What is myelosuppression? Is myelosuppression more likely to occur with neoadjuvant chemotherapy? Myelosuppression is a decrease in bone marrow hematopoiesis or the appearance of no hematopoiesis, which is the most serious side effect of neoadjuvant chemotherapy. Generally speaking, a full dose of chemotherapeutic agent to achieve the effect of chemotherapy will definitely cause myelosuppression. Then, the management of bone marrow suppression is mainly symptomatic support and relief treatment, including relief against chemotherapy drugs, alkalinization of urine, nutritional support, antibiotics to prevent infection, etc. Is there a high incidence of renal injury with neoadjuvant chemotherapy for osteosarcoma? Does it affect the heart? The incidence of kidney injury in neoadjuvant chemotherapy is not high, but there are certain toxic reactions in both liver and kidney. In addition, doxorubicin is an essential drug in neoadjuvant chemotherapy, which can cause some toxic effects on the heart, and we can apply dexrazoxane as a symptomatic antidote.